He is seasoned executive in global healthcare and IVD markets, instrumental in the transformation of the business. He led the group through four acquisitions including Elucigene Diagnostics and Coastal Genomics and the fundraising to underpin those deals. Under his leadership he has grown the business from £30million to greater than £100 million market cap.